Abstract:Objective: Astragalus and Safflower are commonly used in the treatment of stroke. Studies have shown that their two active components, hydroxysafflor yellow A (HSYA) and calycosin (CA), have protective effects on cerebral ischemia-reperfusion injury (I/R). However, the pharmacokinetic-pharmacodynamic (PK-PD) modeling study of the combination of the two components has not been reported in rats. The study aimed to perform combined PKPD modeling of HSYA and CA in normal and cerebral ischemia model rats to explain quantitatively their time concentration-effect relationship. Methods: To make the middle cerebral artery occlusion (MCAO) model. SD rats were randomly divided into normal treated group (NTG) (n = 6), model group (MDG) (n = 6) and model treated group (MTG) (n = 6). Plasma was collected from the mandibular vein after 0, 2, 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 180, and 240 min after intravenous administration. Rats in NTG and MTG were administered the same dose of HSYA (5 mg/kg) and CA (8 mg/kg) by tail vein injection. HPLC-VWD method was used for detection and analysis. Simultaneously, ELISA was performed to detect the levels of IL-1 beta and caspase-9 in rat plasma at different time points. The improvement in the above indicators was compared after administration. Lastly, after combining the pharmacokinetic parameters and pharmacodynamic indicators in vivo, DAS 3.2.6 software was used to fit the PK-PD model. Results: The MCAO model was successfully established. Compared to NTG, there was a significant difference (P < 0.05) in t(1/2 alpha), t(1/2 beta), V-1, V-2, CL1, CL2, AUC((0_t)), AUC ((0-infinity)), and K-12 of MTG for HSYA, and there was a significant difference (P < 0.05) in t(1/2 alpha), V-1, CL1, AUC((0_ t)), AUC ((0-infinity)), and K-10 of MTG for CA. Compared to NTG, the PK parameters of t(1/2 alpha), V-1, V-2, CL1, and K-10 were higher for HSYA in MTG, while AUC((0_t)), AUC ((0-infinity)), K-12, and K-21 were lower; the PK parameters of t(1/2 alpha), V-1, V-2, AUC((0_t)), and AUC((0-infinity)) were higher for CA in MTG, while CL1, CL2, K-10, K-12, and K-21 were lower. Also, the results of PD showed extremely significant differences in the levels of caspase-9 and IL-1 beta at the different time points in MTG (P < 0.01) compared with 0 min. The levels of caspase-9 and IL-1 beta in NTG rats showed little fluctuation and were relatively stable; however, their levels in MTG showed a downward trend with time. There were highly significant differences in the levels of each of the pharmacodynamic indicators at every time point between NTG and MTG (P < 0.01). Conclusion: The PK-PD model of the combined administration of HSYA and CA was successfully established in rats, and the differences in pharmacodynamic and pharmacokinetic properties between the normal and cerebral ischemic rats were evaluated. Based on comprehensive data analysis, we found that the combination of HSYA and CA may exert protective effects against I/R injury in rats via anti-apoptotic and anti-inflammatory pathways. The study provided additional insights into the development of drugs for ischemic stroke as well as the design of appropriate dosing regimens.

First-in-human safety, tolerability, and pharmacokinetics of SY-007, a prolonged action neuroprotective drug for ischemic stroke, in healthy Chinese subjects

Safety, Tolerability, and Pharmacokinetic of HY0721 in Chinese Healthy Subjects: a First-in-human Randomized, Double-Blind, Placebo-Controlled Dose Escalation Phase I Study

Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers

Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies

Preclinical evaluation of ZL006-05, a new antistroke drug with fast-onset antidepressant and anxiolytic effects

Possible Mechanisms Underlying the Protective Effects of Sy-21, an Extract of A Traditional Chinese Herb, on Transient Brain Ischemia/Reperfusion-Induced Neuronal Death in Rat Hippocampus

Pathogenesis-adaptive Polydopamine Nanosystem for Sequential Therapy of Ischemic Stroke

Design, synthesis and biological evaluation of N-salicyloyl tryptamine derivatives as multifunctional neuroprotectants for the treatment of ischemic stroke

A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenol

Abstract 41: Synthesis And Pharmacological Validation Of Novel Neuroprotective Purinergic Receptor P2X4 Antagonists For The Treatment Of Ischemic Stroke

A First-in-human Study of Brozopentyl Sodium, Following Single and Multiple Ascending Intravenous Infusion in Chinese Healthy Volunteers.

Pharmacokinetic-pharmacodynamic Modeling Analysis for Hydroxysafflor Yellow A-calycosin in Compatibility in Normal and Cerebral Ischemic Rats: A Comparative Study.

Protection of Neuronal Cells from Excitotoxicity by Disrupting Nnos-Psd95 Interaction with a Small Molecule SCR-4026.

First-in-Human Phase I Clinical Trial of the Adenosine A1R/A3R Agonist AST-004 in Healthy Subjects

The Neuroprotection of 1,2,4‐Triazole Derivative by Inhibiting Inflammation and Protecting BBB Integrity in Acute Ischemic Stroke

Discovery of benzyloxy benzamide derivatives as potent neuroprotective agents against ischemic stroke

Pharmacokinetic and safety profile of PT109B, a novel multi-targeted compound against Alzheimer's disease

Discovery of neuroprotective Agents: Potent, brain Penetrating, lipoic acid derivatives for the potential treatment of ischemic stroke by regulating oxidative stress and inflammation - a Preliminary study

A randomized, controlled, two-center preclinical trial assessing the efficacy of a new benzodiazepine–dihydropyridine hybrid molecule (JM-20) in rodent models of ischemic stroke

Cytisine–N-methylene-(5,7,4 ' -trihydroxy)- isoflavone ameliorates ischemic stroke-induced brain injury in mouse by regulating the oxidative stress and BDNF-Trkb/Akt pathway